Azeliragon – 10 mg

Brand:
Cayman
CAS:
603148-36-3
Storage:
-20
UN-No:
Non-Hazardous - /

Azeliragon is an orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE; Kd = 12.7 nM for human recombinant sRAGE), which transports amyloid-β (Aβ) from plasma into the CNS.{39734} It is selective for sRAGE over greater than 100 receptors and transporters in a screening assay. Azeliragon (0.3, 1, and 3 mg/kg per day) prevents brain deposition of Aβ (1-40) (Aβ40) and Aβ42 in the APP/SWE/LON transgenic mouse model of Alzheimer’s disease and increases plasma Aβ levels when administered for three months starting at 12 months of age. In the same treatment paradigm, it dose-dependently reduces memory impairments in the Morris water maze compared with untreated control mice, decreasing the latency and distance traveled to the platform. Azeliragon (10 mg/kg) also increases cerebral blood flow in the hippocampus and frontal cortex in tgAPP/SWE/LON mice greater than six months old.  

 

Available on backorder

SKU: 24678 - 10 mg Category:

Description

An inhibitor of RAGE (Kd = 12.7 nM); selective for sRAGE over greater than 100 receptors and transporters in a screening assay; prevents brain deposition of Aβ40 and Aβ42 and reduces impairments in learning and memory tgAPP/SWE/LON mice at 0.3, 1, and 3 mg/kg per day in aged mice; increases cerebral blood flow in the hippocampus and frontal cortext in tgAPP/SWE/LON mice greater than 6 months old


Formal name: 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-1-propanamine

Synonyms: 

Molecular weight: 532.1

CAS: 603148-36-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease